Pemetrexed-induced edema of the eyelid

Takayasu Kurata, Kenji Tamura, Isamu Okamoto, Taroh Satoh, Kazuhiko Nakagawa, Masahiro Fukuoka

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2%, n = 519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.

Original languageEnglish
Pages (from-to)241-242
Number of pages2
JournalLung Cancer
Volume54
Issue number2
DOIs
Publication statusPublished - Nov 1 2006
Externally publishedYes

Fingerprint

Pemetrexed
Eyelids
Edema
Antimetabolites
Pamphlets
Folic Acid
Non-Small Cell Lung Carcinoma
Bone Marrow
Research Personnel
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kurata, T., Tamura, K., Okamoto, I., Satoh, T., Nakagawa, K., & Fukuoka, M. (2006). Pemetrexed-induced edema of the eyelid. Lung Cancer, 54(2), 241-242. https://doi.org/10.1016/j.lungcan.2006.08.002

Pemetrexed-induced edema of the eyelid. / Kurata, Takayasu; Tamura, Kenji; Okamoto, Isamu; Satoh, Taroh; Nakagawa, Kazuhiko; Fukuoka, Masahiro.

In: Lung Cancer, Vol. 54, No. 2, 01.11.2006, p. 241-242.

Research output: Contribution to journalArticle

Kurata, T, Tamura, K, Okamoto, I, Satoh, T, Nakagawa, K & Fukuoka, M 2006, 'Pemetrexed-induced edema of the eyelid', Lung Cancer, vol. 54, no. 2, pp. 241-242. https://doi.org/10.1016/j.lungcan.2006.08.002
Kurata T, Tamura K, Okamoto I, Satoh T, Nakagawa K, Fukuoka M. Pemetrexed-induced edema of the eyelid. Lung Cancer. 2006 Nov 1;54(2):241-242. https://doi.org/10.1016/j.lungcan.2006.08.002
Kurata, Takayasu ; Tamura, Kenji ; Okamoto, Isamu ; Satoh, Taroh ; Nakagawa, Kazuhiko ; Fukuoka, Masahiro. / Pemetrexed-induced edema of the eyelid. In: Lung Cancer. 2006 ; Vol. 54, No. 2. pp. 241-242.
@article{297a29bd1c0f4edc90aeeee25de9ba8c,
title = "Pemetrexed-induced edema of the eyelid",
abstract = "Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2{\%}, n = 519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.",
author = "Takayasu Kurata and Kenji Tamura and Isamu Okamoto and Taroh Satoh and Kazuhiko Nakagawa and Masahiro Fukuoka",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.lungcan.2006.08.002",
language = "English",
volume = "54",
pages = "241--242",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Pemetrexed-induced edema of the eyelid

AU - Kurata, Takayasu

AU - Tamura, Kenji

AU - Okamoto, Isamu

AU - Satoh, Taroh

AU - Nakagawa, Kazuhiko

AU - Fukuoka, Masahiro

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2%, n = 519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.

AB - Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2%, n = 519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.

UR - http://www.scopus.com/inward/record.url?scp=33751096509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751096509&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.08.002

DO - 10.1016/j.lungcan.2006.08.002

M3 - Article

C2 - 16996165

AN - SCOPUS:33751096509

VL - 54

SP - 241

EP - 242

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -